All In Biotech

Drug Trial Radar · NCT03781934

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

A Phase 1/2a Study in 3 Parts to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of MIV-818 in Patients With Liver Cancer Manifestations

Last checked: Nov 20, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

53

Actual

Start

Sep 5, 2018

Primary completion

Jan 7, 2025

Study completion Jun 16, 2025

Sponsor

Lead sponsor
MedivirIndustry
Sponsor type
Industry
First posted
Dec 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.

Conditions

  • Hepatocellular Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Liver Metastases

Interventions

  • MIV-818 (fostroxacitabine bralpamide) + pembrolizumabDrug

    MIV-818 - oral capsules; pembrolizumab - IV

  • MIV-818 (fostroxacitabine bralpamide) + lenvatinibDrug

    MIV-818 - oral capsules; lenvatinib - oral capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of Adverse Events (AEs)Time frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  2. Incidence and magnitude of clinically significant changes in red blood cell count, white blood cell count and platelet countTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  3. Incidence and magnitude of clinically significant changes in aspartate aminotransferase (AST) and alanine aminotransferase (ALT)Time frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  4. Incidence and magnitude of clinically significant changes in bilirubinTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  5. Incidence of clinically significant changes in vital sign - Systolic and diastolic blood pressureTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  6. Incidence of clinically significant changes in vital sign - Pulse rateTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  7. Incidence of clinically significant changes in vital sign - Body TemperatureTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  8. Incidence of clinically significant changes in vital signs - WeightTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months
  9. Incidence of clinically significant changes in ECGsTime frame: Participants monitored throughout treatment period and during follow-up, up to 6 months

Locations

18 sites in 4 countries. Site status is shown where the registry gives one.

  • Antwerp University Hospital

    Antwerp, Belgium

  • University Hospitals Gasthuisberg

    Leuven, Belgium

  • CHA Bundang Medical Center

    Gyeonggi-do, South Korea

  • Pusan National University Hospital

    Pusan, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Hospital Clinic Carrer Rosselló 161

    Barcelona, Spain

  • Hospital Vall Hebrón

    Barcelona, Spain

  • START Barcelona HM Nou Delfos

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • START Madrid-FJD

    Madrid, Spain

  • Beatson West of Scotland Cancer Care

    Glasgow, United Kingdom

  • Guy's Hospital, Oncology and Clinical Trials

    London, United Kingdom

  • Northern Institute for Cancer Research

    Newcastle upon Tyne, United Kingdom

  • Chruchill Hospital, Cancer and Haematology Centre

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.